Fig. 2From: Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE studyTime to treatment discontinuation among study participants who were in the shortened (12 week; n = 61) and standard (24 week; n = 26) armBack to article page